Jennifer Moon

Lucile Packard Children's Hospital — United States

Medicine · Health Sciences

21h-index3.4kcitations64works13.12yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

CAR-T cell therapy research(14), Glioma Diagnosis and Treatment(8), Lipoproteins and Cardiovascular Health(6), Congenital heart defects research(5), Plant Molecular Biology Research(4)

Publications61 total

Pre-CAR next generation sequencing informs patient outcomes in children and young adults with B-acute lymphoblastic leukemia
Blood·2025
Sequential CD19 and CD22 CART for relapsed and refractory B cell ALL: Phase I results
Blood·2025Open Access
269 Humanized anti-CAR antibodies affect durable response to GD2-CAR T-cells in diffuse midline glioma
Regular and Young Investigator Award Abstracts·2025Open Access
CTIM-05. HUMANIZED ANTI-CAR ANTIBODIES AFFECT DURABLE RESPONSE TO GD2-CAR T-CELLS IN DIFFUSE MIDLINE GLIOMA
Neuro-Oncology·2025Open Access
Selective chr21 homolog silencing reveals polymorphisms influence the epigenetic silencing and functional dosage of RWDD2B
2025Open Access
Establishing Concordance of Next Generation Sequencing and Flow Cytometry Measures of B-Cell Recovery Post-CAR T Cell Therapy in B-ALL
Transplantation and Cellular Therapy·2025
Author Correction: Intravenous and intracranial GD2-CAR T cells for H3K27M+ diffuse midline gliomas
Nature·2024· 12 citedOpen Access
Intravenous and intracranial GD2-CAR T cells for H3K27M+ diffuse midline gliomas
Nature·2024· 126 citedOpen Access
IMMU-60. MYELOID POPULATIONS MODULATE GD2 CAR T CELL ACTIVITY IN DIFFUSE MIDLINE GLIOMA
Neuro-Oncology·2024· 1 citedOpen Access
Case report: sub-clinical extramedullary B-ALL in the setting of relapse following targeted therapy
Frontiers in Immunology·2024Open Access
Sequential intravenous and intracerebroventricular GD2-CAR T-cell therapy for H3K27M-mutated diffuse midline gliomas
2024· 6 citedOpen Access
DIPG-47. SEQUENTIAL INTRAVENOUS AND INTRACEREBROVENTRICULAR GD2-CAR T-CELL THERAPY FOR H3K27M-MUTATED DIFFUSE MIDLINE GLIOMAS
Neuro-Oncology·2024Open Access
CD22 CAR T cells demonstrate high response rates and safety in pediatric and adult B-ALL: Phase 1b results
Leukemia·2024· 34 citedOpen Access
Treatment of a genetic liver disease in mice through transient prime editor expression
2024· 4 citedOpen Access
Abstract 959: Immune signatures of GD2 CAR T cell activity in H3K27M+ diffuse midline glioma patients
Cancer Research·2023· 3 cited
Long-Term Follow-up of CD19/22 CAR Therapy in Children and Young Adults with B-ALL Reveals Efficacy, Tolerability and High Survival Rates When Coupled with Hematopoietic Stem Cell Transplantation
Blood·2022· 4 cited
Chromosome silencing in vitro reveals trisomy 21 causes cell-autonomous deficits in angiogenesis and early dysregulation in Notch signaling
Cell Reports·2022· 10 citedOpen Access
Abstract CT001: Major tumor regressions in H3K27M-mutated diffuse midline glioma (DMG) following sequential intravenous (IV) and intracerebroventricular (ICV) delivery of GD2-CAR T cells
Cancer Research·2022· 7 cited
DIPG-15. Major tumor regressions in H3K27M-mutated diffuse midline glioma (DMG) following sequential intravenous (IV) and intracerebroventricular (ICV) delivery of GD2-CAR T-cells
Neuro-Oncology·2022· 2 citedOpen Access
Chromosome silencing <i>in vitro</i> reveals trisomy 21 causes cell-autonomous deficits in angiogenesis and early dysregulation in Notch signaling
2022Open Access
page 1 of 4Next →

Frequent Co-authors

Sneha Ramakrishna(16), Liora M. Schultz(16), Kara L. Davis(16), Christina Baggott(15), Sharon Mavroukakis(14), Emily Egeler(14), Courtney Erickson(14), Bita Sahaf(14), Robbie G. Majzner(13), Steven A. Feldman(13), Rebecca M. Richards(12), Valentin Barsan(12), Jasia Mahdi(12), Michael Kunicki(12), Sonia Partap(12), Cynthia Campen(12), Michelle Monje(12), Ashley Jacobs(12), Michelle Fujimoto(11), Shabnum Patel(10)